Ian Gust
Direktor/Vorstandsmitglied bei BIOTA HOLDINGS LTD.
Aktive Positionen von Ian Gust
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BIOTA HOLDINGS LTD. | Independent Dir/Board Member | 27.07.2001 | - |
| Direktor/Vorstandsmitglied | 27.07.2001 | - | |
| Comptroller/Controller/Auditor | 15.02.2011 | 15.02.2011 | |
| Opal Therapeutics, Inc. | Direktor/Vorstandsmitglied | 09.02.2011 | - |
| Australian International Health Institute | Direktor/Vorstandsmitglied | 09.02.2011 | - |
| Pediatric Dengue Vaccine Initiative | Direktor/Vorstandsmitglied | 09.02.2011 | - |
| Bio21 Australia Ltd. | Vorsitzender | 25.01.2012 | - |
| Direktor/Vorstandsmitglied | 09.02.2011 | 25.01.2012 | |
University of Melbourne
 University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | Corporate Officer/Principal | - | - |
Karriereverlauf von Ian Gust
Ehemalige bekannte Positionen von Ian Gust
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
International Vaccine Institute
 International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | Direktor/Vorstandsmitglied | 01.01.2006 | 01.01.2006 |
| CSL LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1990 | 01.01.2000 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Direktor/Vorstandsmitglied | 09.11.2012 | - |
| ░░░░░░░░░ ░░░░░░ ░░░░░░ ░░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░ ░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | - | - | |
| ░░░░░░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | ░░░░░░░░░░ | |
| ░░░░░░░░░ ░░░░░░░░░ | - | - |
Statistik
International
| Australien | 8 |
| Vereinigte Staaten | 4 |
| Südkorea | 3 |
Operativ
| Director/Board Member | 10 |
| Corporate Officer/Principal | 2 |
| Independent Dir/Board Member | 2 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CSL LIMITED | Health Technology |
| Private Unternehmen | 10 |
|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
| Opal Therapeutics, Inc. | |
Biota Holdings Pty Ltd.
 Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Opal Therapeutics Pty Ltd.
 Opal Therapeutics Pty Ltd. Pharmaceuticals: MajorHealth Technology Opal Therapeutics Pty Ltd develops immunotherapy for HIV and Hepatitis C & chronic infection. The company was founded in 2005 and is headquartered in Melbourne, Australia. | Health Technology |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | Commercial Services |
| Australian International Health Institute | |
| Pediatric Dengue Vaccine Initiative | |
| Bio21 Australia Ltd. | |
| McFarlane Burnet Centre For Medical Research | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
